Hyperspectral imaging signatures detect amyloidopathy in alzheimers mouse retina well before onset of cognitive decline

ACS Chemical Neuroscience

Volumn 6, Issue 2, 2015, Pages 306-315

  More, Swati S ^a   Vince, Robert ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

advanced glycation end products; Alzheimers disease; Hyperspectral imaging (HSI); methylglyoxal; amyloid peptide

Indexed keywords

NOOTROPIC AGENT; PSI GLUTATHIONE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; COGNITION; CONTROLLED STUDY; CORRELATIONAL STUDY; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; HYPERSPECTRAL IMAGING; IMAGING AND DISPLAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RETINA; RETINA DEVELOPMENT; SENSITIVITY AND SPECIFICITY; TREND STUDY; VALIDATION STUDY; AMYLOIDOSIS; ANIMAL; BIOLOGICAL MODEL; BRAIN; C57BL MOUSE; COGNITIVE DEFECT; CYTOPLASM; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES; SPECTROPHOTOMETRY; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; BRAIN; CELL LINE, TUMOR; COGNITION DISORDERS; CYTOPLASM; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, NEUROLOGICAL; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PRESENILIN-1; RETINA; SPECTROPHOTOMETRY; TREATMENT OUTCOME;

EID: 84923253222     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500242z     Document Type: Article

References (42)

1. Herczenik, E. and Gebbink, M. F. (2008) Molecular and cellular aspects of protein misfolding and disease FASEB J. 22, 2115-2133
2. Yerbury, J. J., Stewart, E. M., Wyatt, A. R., and Wilson, M. R. (2005) Quality control of protein folding in extracellular space EMBO Rep. 6, 1131-1136
3. Moore, R. A., Taubner, L. M., and Priola, S. A. (2009) Prion protein misfolding and disease Curr. Opin. Struct. Biol. 19, 14-22
4. Bruce, A., Bray, D., Hopkin, K., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2010) Protein Structure and Function, in Essential Cell Biology, 3 rd ed., pp 120-170, Garland Science, Taylor and Francis Group, New York.
5. Selkoe, D. J. (2003) Folding proteins in fatal ways Nature 426, 900-904
6. Costanzo, M. and Zurzolo, C. (2013) The cell biology of prion-like spread of protein aggregates: Mechanisms and implication in neurodegeneration Biochem. J. 452, 1-17
7. Selkoe, D. J. (2004) Cell biology of protein misfolding: The examples of Alzheimers and Parkinsons diseases Nat. Cell Biol. 6, 1054-1061
8. Lesne, S. E., Sherman, M. A., Grant, M., Kuskowski, M., Schneider, J. A., Bennett, D. A., and Ashe, K. H. (2013) Brain amyloid-beta oligomers in ageing and Alzheimers disease Brain 136, 1383-1398
9. Modler, A. J., Gast, K., Lutsch, G., and Damaschun, G. (2003) Assembly of amyloid protofibrils via critical oligomers-a novel pathway of amyloid formation J. Mol. Biol. 325, 135-148
10. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., and Teplow, D. B. (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate J. Biol. Chem. 272, 22364-22372
11. Yoshimura, Y., Lin, Y., Yagi, H., Lee, Y. H., Kitayama, H., Sakurai, K., So, M., Ogi, H., Naiki, H., and Goto, Y. (2012) Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formation Proc. Natl. Acad. Sci. U.S.A. 109, 14446-14451
12. Roychaudhuri, R., Yang, M., Hoshi, M. M., and Teplow, D. B. (2009) Amyloid beta-protein assembly and Alzheimers disease J. Biol. Chem. 284, 4749-4753
13. Kagan, B. L., Hirakura, Y., Azimov, R., Azimova, R., and Lin, M. C. (2002) The channel hypothesis of Alzheimers disease: current status Peptides 23, 1311-1315
14. Miller, Y., Ma, B., Tsai, C. J., and Nussinov, R. (2010) Hollow core of Alzheimers Aβ42 amyloid observed by cryoEM is relevant at physiological pH Proc. Natl. Acad. Sci. U. S. A. 107, 14128-14133
15. Li, J. J., Dolios, G., Wang, R., and Liao, F. F. (2014) Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression PLoS One 9 e90770
16. Tomiyama, T. (2010) Involvement of beta-amyloid in the etiology of Alzheimers disease Brain Nerve 62, 691-699
17. Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., Cedarbaum, J., Grundman, M., Broich, K., Giacobini, E., Dubois, B., Sperling, R., Wilcock, G. K., Fox, N., Scheltens, P., Touchon, J., Hendrix, S., Andrieu, S., and Aisen, P. 2013, Designing drug trials for Alzheimers disease: What we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dementia 9, 438-444
18. Verdooner, S. (2013) Apparatus and method for imaging an eye, International Patent WO201111602A2.
19. Groenning, M. (2010) Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status J. Chem. Biol. 3, 1-18
20. Zovo, K., Helk, E., Karafin, A., Tougu, V., and Palumaa, P. (2010) Label-free high-throughput screening assay for inhibitors of Alzheimers amyloid-beta peptide aggregation based on MALDI MS Anal. Chem. 82, 8558-8565
21. McKoy, A. F., Chen, J., Schupbach, T., and Hecht, M. H. (2012) A novel inhibitor of amyloid β (Aβ) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimers disease J. Biol. Chem. 287, 38992-39000
22. Ahn, B. W., Song, D. U., Jung, Y. D., Chay, K. O., Chung, M. A., Yang, S. Y., and Shin, B. A. (2000) Detection of β-amyloid peptide aggregation using DNA electrophoresis Anal. Biochem. 284, 401-405
23. Hu, X., Crick, S. L., Bu, G., Frieden, C., Pappu, R. V., and Lee, J. M. (2009) Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide Proc. Natl. Acad. Sci. U. S. A. 106, 20324-20329
24. Li, J., Kanekiyo, T., Shinohara, M., Zhang, Y., LaDu, M. J., Xu, H., and Bu, G. (2012) Differential Regulation of Amyloid-β Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein E Isoforms J. Biol. Chem. 287, 44593-44601
25. Quinten, M. and Stier, J. (1995) Absorption of Scattered Light in Colloidal Systems of Aggregated Particles Colloid Polym. Sci. 273, 233-241
26. Veloso, A. J., Yoshikawa, H., Cheng, X. R., Tamiya, E., and Kerman, K. (2011) Optical Trapping for the Characterization of Amyloid-Beta Aggregation Kinetics Analyst 136, 4164-4167
27. Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., and Cerami, A. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimers disease Proc. Natl. Acad. Sci. U. S. A. 91, 4766-4770
28. Tilton, R. G., Chang, K., Hasan, K. S., Smith, S. R., Petrash, J. M., Misko, T. P., Moore, W. M., Currie, M. G., Corbett, J. A., McDaniel, M. L., and Williamson, J. R. (1993) Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation Diabetes 42, 221-232
29. Subratty, A. H., Aukburally, N., Jowaheer, V., and Joonus, N. (2010) Vitamin C and urea inhibit the formation of advanced glycation end products in vitro Nutr. Food Sci. 40, 456-465
30. Esler, W. P., Stimson, E. R., Jennings, J. M., Ghilardi, J. R., Mantyh, P. W., and Maggio, J. E. (1996) Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro J. Neurochem. 66, 723-732
31. Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, C. A., Ko, M. K., Black, K. L., Schwartz, M., and Farkas, D. L. (2011) Identification of amyloid plaques in retinas from Alzheimers patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model Neuroimage 54, S204-S217
32. Berisha, F., Feke, J. T., Trempe, C. L., McMeel, J. W., and Schepens, C. L. (2007) Retinal abnormalities in early Alzheimers disease Invest. Ophthalmol. Vis. Sci. 48, 2285-2289
33. Blanks, J. C., Schmidt, S. Y., Torigoe, Y., Porrello, K. V., Hinton, D. R., and Blanks, R. H. (1996) Retinal pathology in Alzheimers disease. II. Regional neuron loss and glial changes in GCL Neurobiol. Aging 17, 385-395
34. Paquet, C., Boissonnot, M., Roger, F., Dighiero, P., Gil, R., and Hugon, J. (2007) Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimers disease Neurosci. Lett. 420, 97-99
35. Parisi, V., Restuccia, R., Fattapposta, F., Mina, C., Bucci, M. G., and Pierelli, F. (2001) Morphological and functional retinal impairment in Alzheimers disease patients Clin. Neurophysiol. 112, 1860-1867
36. Drexler, W., Morgner, U., Ghanta, R. K., Kartner, F. X., Schuman, J. S., and Fujimoto, J. G. (2001) Ultrahigh-resolution ophthalmic optical coherence tomography Nat. Med. 7, 502-507
37. More, S. S., Vartak, A. P., and Vince, R. (2013) Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimers disease ACS Chem. Neurosci. 4, 330-338
38. Morris, R. (1984) Developments of a water-maze procedure for studying spatial learning in the rat J. Neurosci. Methods 11, 47-60
39. Aikio, M. (2001) Hyperspectral prism-grating-prism imaging spectrograph, Ph.D. Thesis, University of Oulu, Publ. 435, VTT Publications, Espoo, Finland.
40. Robila, S. A. (2004) An analysis of spectral metrics for hyperspectral image processing. Geoscience and Remote Sensing Symposium, IGARSS 04. Proceedings. 2004, Vol. 5, pp 3233 - 3236, IEEE International, Piscataway, NJ.
41. Zhang, J., Zhu, W., Wang, L., and Jiang, N. (2012) Evaluation of similarity measure methods for hyperspectral remote sensing data. Geoscience and Remote Sensing Symposium (IGARSS), 2012, pp 4138 - 4141, IEEE International, Piscataway, NJ.
42. Pitulescu, M. E., Schmidt, I., Benedito, R., and Adams, R. H. (2010) Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice Nat. Protoc. 5, 1518-1534